Profil
Stefanos Theoharis currently works at OneChain Immunotherapeutics SL, as Chief Executive Officer from 2024.
Dr. Theoharis also formerly worked at The London Technology Network, as Consultant, Isarna Therapeutics GmbH, as Head-Business Development from 2011 to 2013, and Bone Therapeutics SA, as Chief Business Officer.
Dr. Theoharis received his graduate degree and doctorate degree from Imperial College London and undergraduate degree from Royal Holloway University of London.
Postes actifs de Stefanos Theoharis
| Sociétés | Poste | Début |
|---|---|---|
Onechain Immunotherapeutics
Onechain Immunotherapeutics Medical SpecialtiesHealth Technology Develops oncological therapeutic tools | Directeur Général | 01/02/2024 |
Anciens postes connus de Stefanos Theoharis
| Sociétés | Poste | Fin |
|---|---|---|
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Develops cytokine human transforming growth factor-beta (TGF-beta) inhibitors | Corporate Officer/Principal | 01/02/2013 |
| BIOSENIC SA | Corporate Officer/Principal | - |
The London Technology Network
The London Technology Network Other Consumer ServicesConsumer Services Provides academic training in computer science, life science, and physical science | Corporate Officer/Principal | - |
Formation de Stefanos Theoharis
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Imperial College London
Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The London Technology Network
The London Technology Network Other Consumer ServicesConsumer Services Provides academic training in computer science, life science, and physical science | Consumer Services |
Royal Holloway University of London
Royal Holloway University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Develops cytokine human transforming growth factor-beta (TGF-beta) inhibitors | Health Technology |
Bone Therapeutics SA
Bone Therapeutics SA Pharmaceuticals: MajorHealth Technology Develops regenerative therapy products for addressing unmet medical needs in the field of bone diseases and orthopedics | Health Technology |
Onechain Immunotherapeutics
Onechain Immunotherapeutics Medical SpecialtiesHealth Technology Develops oncological therapeutic tools | Health Technology |
















